Phio Pharmaceuticals Corp. (PHIO) is a publicly traded company in the Unknown sector. Across all available filings, 14 corporate insiders have executed 104 transactions totaling $70.5K, demonstrating a bullish sentiment with $70.5K in net insider flow. The most recent transaction on Feb 5, 2026 involved a transaction of 120,000 shares valued at $0.
No significant insider buying has been recorded for PHIO in the recent period.
No significant insider selling has been recorded for PHIO in the recent period.
Based on recent SEC filings, insider sentiment for PHIO is bullish with an Insider Alignment Score of 100/100 and a net flow of $70.5K. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Phio Pharmaceuticals Corp. (PHIO) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 14 insiders are actively trading PHIO stock, having executed 104 transactions in the past 90 days. The most active insider is Geert Cauwenbergh (Executive), who has made 13 transactions totaling $137.8K.
Get notified when executives and directors at PHIO file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 5, 2026 | J. Bitterman Robert | Executive | Award | 120,000 | $N/A | $0 | |
| Feb 5, 2026 | A. Bradford Patricia | Executive | Award | 18,500 | $N/A | $0 | |
| Feb 5, 2026 | Cabott Carson Lisa | Chief Financial Officer | Award | 47,000 | $N/A | $0 | C-Suite |
| Feb 5, 2026 | H. Deming David | Executive | Award | 23,800 | $N/A | $0 | |
| Feb 5, 2026 | E. Freeman Jonathan | Executive | Award | 16,600 | $N/A | $0 | |
| Feb 5, 2026 | Lockshin Curtis | Executive | Award | 16,600 | $N/A | $0 | |
| Dec 23, 2025 | J. Bitterman Robert | Executive | Purchase | 5,000 | $1.02 | $5.1K | |
| Nov 21, 2025 | J. Bitterman Robert | Executive | Purchase | 5,000 | $1.14 | $5.7K | |
| Nov 18, 2025 | J. Bitterman Robert | Executive | Purchase | 5,000 | $1.27 | $6.3K | |
| Sep 11, 2025 | J. Bitterman Robert | Executive | Award | 250,000 | $N/A | $0 | |
| Sep 11, 2025 | J. Bitterman Robert | Executive | Payment | 4,111 | $2.32 | $9.5K | |
| Sep 11, 2025 | A. Bradford Patricia | Executive | Award | 18,800 | $N/A | $0 | |
| Sep 11, 2025 | Cabott Carson Lisa | Executive | Award | 47,000 | $N/A | $0 | |
| Sep 11, 2025 | L. Ferrara Robert | Executive | Award | 23,000 | $N/A | $0 | |
| Sep 11, 2025 | E. Freeman Jonathan | Executive | Award | 14,700 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Award(A) | 68 | $238.6K | 69.8% |
Purchase(P) | 22 | $70.5K | 20.6% |
Payment(F) | 14 | $32.7K | 9.6% |
Insiders at Phio Pharmaceuticals Corp. are accumulating shares at an accelerated pace. With 14 insiders making 104 transactions totaling $70.5K in purchases versus $0 in sales, the net buying activity of $70.5K signals strong executive confidence. Geert Cauwenbergh (Executive) leads the buying activity with $137.8K in transactions across all time.